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Antimicrobial Resistance among Gram-negative Isolates in
Haematology-oncology Patients: Ecological Analysis in a
University Hospital
Matteo Bassetti, Ernestina Carla Repetto, Alessandra Mularoni,
Laura Ambra Nicolini, Emanuele Malfatto, Stefania Mannelli,
Claudio Giacomazzi, Oliviero Varnier, Marco Gobbi,
Franco Dallegri, Claudio Viscoli. Infectious Diseases Division, S.
Martino Hospital and University of Genoa School of Medicine,
Genoa, Italy
Background: Prophylactic treatment with oral fluoroquinolones,
mainly levofloxacin in neutropenic patients has been found to be
useful for preventing Gram-negative bacteraemia and has become
a popular and standard preventive-therapy strategy in many cancer
centres. Moreover, intravenous anti-pseudomonal antibiotics rep-
resent the first choice in empirical therapy of febrile neutropenic
inpatients.
Objectives: To find a difference in the pattern of resistance of
the evaluated organisms among hemato-oncologic patients after
the introduction of quinolones prophylaxis, starting on 2002. Sec-
ondary aim was finding other statistically significative changes in
pattern of resistance among the other considered classes of antibi-
otics.
Methods: Retrospective observational study was conducted con-
sidering significant isolates obtained from respiratory tract sam-
ples (tracheo-aspirates and BAL) and blood, urine and swabs
cultures from inpatients of 2 hemato-oncology wards (30 beds)
of San Martino University Hospital (Genoa, Italy) from 2000 to
2005. Two groups of pathogens were considered for the anal-
ysis: Gram-negative fermenters (GNF) (Enterobacteriaceae) and
non fermenters (GNNF) (P. aeruginosa, S. maltophilia, B. cepa-
cia, A. baumannii). The rates of resistance to 5 top used an-
tibiotics: ciprofloxacin (CIP), amikacin (AMK), ceftazidime (CAZ),
piperacillin-tazobactam (TZP) and imipenem (IMI) have been anal-
ysed. χ2 test for statistical analysis was used.
Results: 185 GNNF and 597 GNF were isolated in the study period.
Among GNF, we found a difference of resistance to CIP from (20%
versus 34%, p=0.02) and to CAZ (3% versus 13%, p= 0.008), not for
AMK, TZP and IMI. Among GNNF we have found no statistical dif-
ferences of resistance crossing the years. For the detailed results
see table.
GNF resistance 2000 2001 2002 2003 2004 2005
CIP 20% 21% 36%* 45%* 52%* 34%*
CAZ 3% 2% 7% 1% 7% 13%**
*Compared to year 2000 p<0.02, **compared to 2000 p=0.008.
Conclusions: A statistically significant trend in CIP and CAZ resis-
tance among GNF has been found. Despite little number of iso-
lates and the lack of clinical history and outcome of patients, our
data showed that empirical treatment and popular levofloxacin
prophylaxis have impact on the resistance ecology in the hemato-
oncologic departments. The study underlines the importance of
knowing the local "ward" epidemiology to optimise empiric antibi-
otic therapy.
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Outcome with Early Oral Voriconazole Therapy in 73
AML-MDS Patients with Invasive Aspergillosis
Bart Rijnders, Lennert Slobbe, Pieternella Lugtenburg,
Jeanette Doorduijn. Erasmus MC, Dept. of Internal Medicine,
Section of Infectious Diseases, Rotterdam, the Netherlands
Background: Invasive aspergillosis (IA) is a leading cause of mor-
bidity and mortality in patients with AML/MDS. Current standard
of care is treatment with voriconazole. In the registration trial
voriconazole was given intravenously for the first 8 days but the
bioavailability of oral voriconazole is excellent. Therefore we de-
cided to give voriconazole orally during the first 8 days of therapy
if oral intake was possible. We here describe our experience in a
large group of patients with AML/MDS and IA.
Methods: In 269 consecutive patients treated for AML/MDS from
2002 to 2007, evidence for IA was collected using HRCT for the
evaluation of neutropenic fever and galactomannan measurement
in broncho-alveolar lavage fluid of intrapulmonary lesions. IA was
classified according to the recently updated EORTC-MSG defini-
tions. All cause mortality 12 weeks after the start of antifungal
therapy was registered. For the evaluation of attributable mortal-
ity of IA we compared all cause mortality 12 weeks after the last
course of anti-leukemic therapy between patients with and without
IA. Voriconazole treatment was given orally from day 1 whenever
oral intake was possible. The same dosing regimen as was given
intravenously in the study by Herbrecht et al was used orally (Her-
brecht R et al. 2002).
Results: 80 patients developed IA, 48 (18%) of them had probable
or proven infection and 32 (12%) had possible IA. 6 were treated
with amphotericin-B in 2002 before voriconazole became available
in the Netherlands and 1 patient received itraconazole. 73 patients
were treated with voriconazole; 55 (75%) were able to take oral
voriconazole from day 1. Overall mortality 12 weeks after the start
of voriconazole was 22% (16/73). This compares favourably with
the study by Herbrecht et al. where a 12 week overall mortality of
29% was reported with voriconazole and 42% when amphotericin-B
deoxycholate was used. The overall mortality 12 weeks after the
last course of anti-leukemic therapy was 26% in IA-patients com-
pared to 16% in IA-free patients (p=0.06) with a hazard ratio of
dying for patients with IA of 2.4 (95% CI, 1.3 -4.4) in a cox regres-
sion analysis.
Conclusions: Early diagnosis with HRCT, galactomannan measure-
ment in BAL and treatment of IA with oral voriconazole results in
an acceptable 12-week mortality.
Reference: Herbrecht R et al. Voriconazole versus amphotericin B
for primary therapy of invasive aspergillosis. N Engl J Med. 2002
Aug 8;347(6):408-15.
74
Septifast PCR for the Microbiological Documentation of
Infections in Febrile Neutropenic Patients
Frédéric Lamoth, Katia Jaton-Ogay, Thierry Calandra,
Guy Prodhom, Laurence Senn, Jacques Bille, Oscar Marchetti.
Centre Hospitalier Universitaire Vaudois and University of
Lausanne, Infectious Diseases Service and Microbiology Institute,
Lausanne, Switzerland
Background: Blood cultures are the gold standard of microbiologi-
cal diagnosis in febrile neutropenic patients. However, no causative
agent is identified in 2/3 of febrile episodes. Septifast (Roche) is a
new PCR test, which may detect bacterial and fungal DNA in blood
(spectrum of 25 bloodstream pathogens).
Objective: To assess the utility of Septifast PCR for the microbio-
logical documentation of febrile neutropenia.
Methods: Blood samples for blood cultures and Septifast PCR were
prospectively drawn in 100 adult neutropenic cancer patients at
D0 (onset of fever) and D3 (if persistent fever). Febrile episodes
were classified as microbiologically (MDI) or clinically documented
infection (CDI) and fever of unknown origin (FUO) according to the
results of blood cultures.
Results: 237 samples were analyzed in 146 febrile episodes (51
MDI, 51 CDI, 44 FUO). Blood cultures and Septifast were positive in
39 (27%) and 51 (35%) episodes, respectively. The pathogens were:
